Genmab and Seagen Announce U.S. FDA Filing Acceptance for Priority Review of Tisotumab Vedotin Biologics License Application for Patients with Recurrent or Metastatic Cervical Cancer
Company Announcement FDA action date is Oct 10, 2021 BLA submission supported by positive pivotal…